Return to content in this issue


Reply to: Successful Isatuximab Desensitization in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis

Torres Górriz MC1,2,3, Borrás Cuartero J3,4, Pesántez Méndez CG1,3, Stein Coronado CI1,3, Enrique E1,2,3

1Allergy Department, Castellon University General Hospital, Castellón, Spain
2Doctoral School, Jaume I University, Castellon de la Plana, Spain
3FISABIO Foundation Research Group
4Allergy Department, Castellon Provincial Hospital Consortium, Castellón, Spain

J Investig Allergol Clin Immunol 2024; Vol. 34(3)
doi: 10.18176/jiaci.0992

Key words: Isatuximab, Desensitization, Hypersensitivity reaction, Monoclonal antibody, Anaphylactic shock